NRXS · Neuraxis, INC · Executive Compensation
$5.74
+0.05 (+0.88%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$72.08M
Shares
12.56M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brian Carrico | Chief Executive Officer | $839,398 |
| Dr. Thomas Carrico | Chief Regulatory Officer | $411,097 |
| Dr. Adrian Miranda | Chief Medical Officer | $323,052 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brian Carrico | Chief Executive Officer | $392,179 |
| Dr. Thomas Carrico | Chief Regulatory Officer | $287,196 |
| Dr. Adrian Miranda | Chief Medical Officer | $284,947 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Gil Aharon | the Board | Appointed | 2024-11-25 |
Key facts
CIK
1933567
CUSIP
64134X201
13F (30d)
19 filings
19 filers
Visit website
Investor relations